Most cardiac sarcoidosis patients respond to six months of first-line treatment with the corticosteroid prednisolone and show reduced active inflammation in the heart, according to a small study in Japan. Cardiovascular events were less common among responders relative to those who respondly poorly, further confirming first-line prednisolone’s effectiveness…

“Be who you are and say what you feel, because those who mind don’t matter, and those who matter don’t mind.” — Anonymous Every other week before I meet with my therapist, I take stock of where my head is at: what I’m thinking most about, what’s stressing me…

“Start where you are. Use what you have. Do what you can.” — tennis champion Arthur Ashe Six years ago, my life changed. That’s when I experienced my first spontaneous pneumothorax, or a sudden collapsed lung. The year before, I’d been laid off from my job. I spent that…

“Baseball is 90% mental. The other half is physical.” — New York Yankees Hall of Famer Yogi Berra It seems we’re never going to make it to a post-COVID world. It’s never going to be gone — or if it is, other variants or viruses will likely take its place.

Patterns of multiorgan involvement in African Americans with sarcoidosis differ from those of Americans of European ancestry, a study suggests. But in both groups, certain genetic mutations are associated with specific patterns of organ involvement. Collectively, its findings “support ancestry-specific differences likely resulting from distinct social, cultural, and environmental…

When I told my primary physician a few months ago that I was diagnosed with avascular necrosis (also known as AVN or osteonecrosis) and would be having a total hip replacement in early June, he offered his sympathies. I understood that inclination, but I was thrilled. I would have…

Meitheal Pharmaceuticals has entered into an agreement with Xentria to market XTMAB-16, the investigational treatment for pulmonary sarcoidosis, should it be approved in the future. Under the terms of the agreement, Meitheal gains the sole rights to sell and distribute XTMAB-16 in North America. Xentria retains the…

Greater exposure to the experimental treatment efzofitimod led to a more pronounced improvement in lung function for people with pulmonary sarcoidosis in a Phase 1/2 clinical trial, according to a new analysis. Scientists at aTyr Pharma, the company developing the first-in-class immunomodulatory therapy, presented their findings at…

Patient and physician education, trust-building, and support mechanisms are needed to reduce barriers to clinical trial participation for Black people with sarcoidosis, according to a paper by the Foundation for Sarcoidosis Research (FRS). The white paper was titled “Ignore No More Campaign on Clinical Trials…

“People will forget what you said, people will forget what you did, but people will never forget how you made them feel.” While the origins of this quote are uncertain, it is often attributed to writer and activist Maya Angelou. But even if Angelou didn’t actually say this, she…